Mirati Therapeutics, Inc. (NASDAQ:MRTX) saw some unusual options trading activity on Monday. Traders bought 641 call options on the company. This is an increase of 871% compared to the average daily volume of 66 call options.
A number of equities analysts have recently weighed in on the company. HC Wainwright upped their target price on Mirati Therapeutics to $40.00 and gave the company a “buy” rating in a report on Monday. ValuEngine upgraded Mirati Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. Barclays assumed coverage on Mirati Therapeutics in a report on Monday. They issued an “overweight” rating and a $44.00 target price on the stock. Oppenheimer reiterated a “buy” rating and issued a $18.00 target price on shares of Mirati Therapeutics in a report on Wednesday, November 22nd. Finally, Citigroup upped their target price on Mirati Therapeutics from $23.00 to $37.00 and gave the company a “buy” rating in a report on Monday, March 5th. Three equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $25.44.
In other news, SVP Jamie Christensen sold 23,000 shares of the company’s stock in a transaction dated Tuesday, February 6th. The stock was sold at an average price of $30.00, for a total value of $690,000.00. Following the transaction, the senior vice president now owns 10,877 shares in the company, valued at approximately $326,310. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Jamie A. Donadio sold 51,875 shares of the company’s stock in a transaction dated Thursday, March 1st. The shares were sold at an average price of $27.13, for a total value of $1,407,368.75. Following the completion of the transaction, the chief financial officer now owns 9,375 shares in the company, valued at approximately $254,343.75. The disclosure for this sale can be found here. Insiders have sold 112,914 shares of company stock valued at $3,054,250 over the last ninety days. Insiders own 5.10% of the company’s stock.
Mirati Therapeutics (MRTX) opened at $34.95 on Tuesday. Mirati Therapeutics has a twelve month low of $2.70 and a twelve month high of $37.62. The company has a market capitalization of $1,001.33, a P/E ratio of -12.53 and a beta of 2.06.
Mirati Therapeutics (NASDAQ:MRTX) last released its quarterly earnings data on Thursday, March 8th. The biotechnology company reported ($0.67) EPS for the quarter, missing analysts’ consensus estimates of ($0.61) by ($0.06). equities research analysts forecast that Mirati Therapeutics will post -2.49 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “Traders Purchase Large Volume of Call Options on Mirati Therapeutics (MRTX)” was first posted by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international trademark & copyright law. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2018/03/13/traders-purchase-large-volume-of-call-options-on-mirati-therapeutics-mrtx.html.
Mirati Therapeutics Company Profile
Mirati Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of oncology products. The companys clinical stage product candidates include glesatinib, an orally-bioavailable, potent, small molecule kinase inhibitor that is in Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC) patients with genetic alterations of MET; and in Phase Ib clinical trials in patients with genetic alterations of MET and Axl in NSCLC and other solid tumors.
Receive News & Ratings for Mirati Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.